Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 1/20 | 0.38 |
| ▸ | POLG | P54098 | 1/20 | 0.34 |
| ▸ | DCK | P27707 | 2/20 | 0.31 |
| ▸ | EP300 | Q09472 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5496877 | 0.82 | ALB (0.38) | ALBPOLGDCKEP300LMNA | |
| SCHEMBL5494931 | 0.76 | AHCY (0.46) | LMNA | |
| SCHEMBL1738785 | 0.74 | ALB (0.43) | ALBPOLGDCKEP300LMNA | |
| SCHEMBL5496885 | 0.71 | ADORA2A (0.35) | — | |
| SCHEMBL10015803 | 0.70 | ALB (0.46) | ALBPOLGDCKLMNA | |
| Elvucitabine SCHEMBL3298257 | 0.69 | ALB (0.55) | ALBPOLGDCKLMNA | |
| SCHEMBL12149519 | 0.69 | ALB (0.44) | ALBPOLGDCKEP300LMNA | |
| Dexelvucitabine SCHEMBL599014 | 0.69 | ALB (0.55) | ALBPOLGDCKLMNA | |
| Elvucitabine SCHEMBL1649928 | 0.69 | ALB (0.55) | ALBPOLGDCKLMNA | |
| SCHEMBL12149532 | 0.69 | ALB (0.44) | ALBPOLGDCKEP300LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1654270-B1 | PROCESS FOR PREPARING 2',3'-DIDEHYDRO-2',3'-DIDEOXYNUCLEOSIDES AND 2',3'-DIDEOXYNUCLEOSIDES | ARCHIMICA SRL (IT) | 2007-12-26 | — | — | EP | disclosed |
| US-20060199959-A1 | Process for preparing 2',3'-didehydro-2'3'-dideoxynucleosides and 2',3'-dideoxynucleosides | ARCHIMICA S.R.L. (IT) | 2006-09-07 | — | — | US | disclosed |
| EP-1654270-A1 | PROCESS FOR PREPARING 2',3'-DIDEHYDRO-2',3'-DIDEOXYNUCLEOSIDES AND 2',3'-DIDEOXYNUCLEOSIDES | Clariant Life Science Molecules (Italia) S.p.A. (IT) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005012325-A1 | PROCESS FOR PREPARING 2',3'-DIDEHYDRO-2',3'-DIDEOXYNUCLEOSIDES AND 2',3'-DIDEOXYNUCLEOSIDES | CLARIANT LIFE SCIENCE MOLECULES (ITALIA) S.P.A. (IT) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199959-A1 | Process for preparing 2',3'-didehydro-2'3'-dideoxynucleosides and 2',3'-dideoxynucleosides | DOHH, UMPS, DCPS | ALB 3795/4885POLG 164/4885DCK 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.